Eli Lilly CEO Says Tax Reform May Lead to More Successful Deals

Drugmaker wants to build up its pipeline in cancer, diabetes
Tax-law changes will affect Lilly’s operations in Puerto Rico

An Eli Lilly & Co. logo is seen on a pill bottle in this arranged photograph at a pharmacy in Princeton, Illinois, U.S., on Monday, Oct. 23, 2017.

Photographer: Daniel Acker/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Cynthia Koons and Jared S Hopkins

January 8, 2018 at 9:14 PM UTC

This article is for subscribers only.

Eli Lilly & Co. Chief Executive Officer Dave Ricks said on Monday that the recent changes in U.S. tax policy will help the drugmaker lower its global tax burden as he continues to look for deals in areas like oncology.

“We may win a few more contests that we were losing before,” he said in an interview at the annual J.P. Morgan Healthcare Conference in San Francisco.